

Research Article

Speciation Studies of Diorganotin(IV) Complexes with 3,3-Bis(1-methylimidazol-2-yl)propionate—Displacement Reaction by DNA Constituents

Mohamed M. Shoukry^{1,2} and Safaa S. Hassan²

¹ Department of Chemistry, Faculty of Science, Islamic University, Madina 170, Saudi Arabia

² Department of Chemistry, Faculty of Science, Cairo University, Cairo 12613, Egypt

Correspondence should be addressed to Mohamed M. Shoukry; shoukrymm@hotmail.com

Received 15 August 2013; Accepted 17 September 2013

Academic Editors: M. Pellei and A. Souldozi

Copyright © 2013 M. M. Shoukry and S. S. Hassan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The interaction of 3,3-bis(1-methylimidazol-2-yl)propionate (BIMP) with dimethyltin(IV) dichloride (DMT), dibutyltin(IV) dichloride (DBT), and diphenyltin(IV) dichloride (DPT) is investigated at 25°C and 0.1 M ionic strength in water for dimethyltin(IV), and in a 50% dioxane-water mixture for dibutyltin(IV) and diphenyltin(IV). The stepwise formation constants of the 1:1 and 1:2 complexes formed in solution are calculated from potentiometric measurements using the nonlinear least-square program MINQUAD-75. The concentration distribution of the various complex species is evaluated as a function of pH. Displacement reactions of the coordinated 3,3-bis(1-methylimidazol-2-yl)propionate by inosine and inosine-5'-monophosphate are investigated from calculations based upon equilibrium properties.


1. Introduction

There has been tremendous research in recent years concerning the design of nonplatinum chemotherapeutics with the aim to optimize the features of classical platinum drugs constituting the basic cisplatin framework without some of their drawbacks, namely, toxic side effects, inherent intrinsic resistance, and high cost [1]. Among other noteworthy possibilities, some organotin compounds have emerged as a promising class of cancer chemotherapeutics.


The antitumour properties of tin complexes have been established since 1929 [2] and Gielen [3] has published a series of research papers on this subject during the past two decades. The diorganotin (IV) antitumour complexes showed high *in vitro* activity against P388 leukaemia in mice as well as in some human tumour cell lines [4–10]. Numerous diorganotin (IV) derivatives have been found to exhibit high *in vivo* cytotoxicity against P388 lymphocytic leukaemia and to exhibit less or no activity against other murine systems [11]. However, the new *in vitro* human tumour cell screening tests have once again demonstrated the potential of organotin

complexes, some of which have exhibited high activity [12], and thus interest in them has been revitalized.

Organotin (IV) compounds exhibiting potent anticancer activity may act via different mechanisms at the molecular level. The binding property of organotin compounds towards DNA, the ultimate drug target molecule, depends essentially on the coordination number/stereochemistry and the nature of groups directly attached to the tin scaffold [13]. Recently, there have been reports of the interaction of Sn compounds with DNA constituents [14–16]. The antitumour activity of the coordination compounds $R_2SnX_2L_2$ is controlled by the nature of R, leaving groups (X) and the ligand (L). The coordinated ligand (L) favours in some way the transport of the drugs into cells, while the antitumour activity would be exerted by the diorganotin(IV) moiety dissociated from the complex [17]. The latter would interact with nucleic acids, in a similar way as in the case of the widely used anticancer drug cisplatin. Therefore, there is a relationship between the stability of the organotin(IV) compounds and their antitumor activity. In conjunction with our previous studies on organotin (IV) complexes [18–22], the present paper aims to study



3,3-bis(1-methylimidazol-2-yl)propionic acid



Inosine

Inosine-5'-monophosphate

SCHEME 1: Chemical structure of investigated ligands.


dimethyl-, dibutyl-, and diphenyltin(IV) complexes with 3,3-bis(1-methylimidazol-2-yl)propionate (BIMP). The displacement reaction of coordinated (BIMP) by inosine and inosine-5'-monophosphate, taken as representative examples of DNA constituents, is investigated. The equilibrium constant for the displacement reaction is a parameter that may be significant to the antitumor activity of organotin(IV) compounds.

2. Experimental

Dimethyltin(IV) dichloride(DMT), dibutyltin(IV) dichloride (DBT), and diphenyltin(IV) dichloride (DPT) were obtained from the Merck Chem. Co. 3,3-bis(1-methylimidazol-2-yl)propionate (BIMP) was prepared as described previously [23]. Inosine and inosine-5'-monophosphate were obtained from Aldrich Chem. Co. The chemical structure of the investigated ligands were given in Scheme 1. Carbonate-free NaOH (titrant) was prepared and standardized against potassium hydrogen phthalate solution. DMT solution was prepared in water, but DBT and DPT solutions were prepared in dioxane. BIMP solution was prepared in the protonated form by dissolving in HNO₃ solution.

Potentiometric measurements were made using a Metrohm 686 titroprocessor equipped with a 665 Dosimat (Switzerland). The titroprocessor and electrode were calibrated with standard buffer solutions and prepared according to NBS specifications [24]. The titrations were carried out in a purified N₂ atmosphere using a titration vessel described previously [25]. The temperature was maintained constant by a Colora ultrathermostat. The protonation constants of 3,3-bis(1-methylimidazol-2-yl)propionic acid in the protonated form were determined by titrating 40 mL of a 2.5 × 10⁻³ M

solution. The hydrolysis constants of the DMT, DBT, and DPT compounds were determined by titrating 40 mL solution of concentration 2.5 × 10⁻³ M of each compound. The formation constants of organotin(IV) complexes were determined by titrating 40 mL of solution containing 3,3-bis(1-methylimidazol-2-yl)propionate (2.5 × 10⁻³ M) and a given organotin(IV) compound with a concentration of 1.25 × 10⁻³ M. The titration was performed at 25°C and in water for DMT but in 50% dioxane-water solution for DBT and DPT. The *pK_w* in dioxane-water solution was determined as described previously [22, 26]. For this purpose, various amounts of standard NaOH solution were added to a solution containing 0.1 M NaNO₃. The [OH⁻] was calculated from the amount of base added. The [H⁺] was calculated from the pH value. The product of [OH⁻] and [H⁺] was taken. The mean value obtained in this way for the log concentration product is *pK_w* = 15.46 for 50% dioxane-water solution. The equilibrium constants were evaluated from titration data defined by



$$\beta_{pqr} = \frac{[(M)_p(L)_q(H)_r]}{[M]^p[L]^q[H]^r}, \quad (2)$$

where M, L, and H represent organotin(IV), 3,3-bis(1-methylimidazol-2-yl)propionate, and proton, respectively. The calculations were performed using the computer program MINQUAD-75 [27]. The stoichiometries and stability constants of the complexes formed were determined by trying various possible composition models. The model selected gave the best statistical fit and was chemically consistent with the titration data without giving any systematic drifts in

TABLE 1: Formation constants of organotin(IV) complexes with 3,3-bis(1-methylimidazol-2-yl)propionate in water for DMT and in 50% (v/v) dioxane-water solution for DBT and DPT, at 25°C and 0.1 M ionic strength.

Organotin(IV)	p^a	q^a	r^a	$\log\beta^b$
DMT	0	1	1	7.11 (0.01)
	0	1	2	11.31 (0.02)
	0	1	3	13.49 (0.03)
	1	0	-1	-3.39 (0.01)
	1	0	-2	-8.99 (0.01)
	1	0	-3	-19.83 (0.01)
	1	0	-4	-31.30 (0.01)
	2	0	-2	-3.92 (0.01)
	1	1	0	9.47 (0.02)
	1	2	0	14.78 (0.11)
DBT	1	1	-1	4.70 (0.11)
	0	1	1	6.66 (0.01)
	0	1	2	10.98 (0.02)
	0	1	3	14.43 (0.02)
	1	0	-1	-4.39 (0.01)
	1	0	-2	-15.05 (0.02)
	2	0	-1	-1.41 (0.04)
	1	1	0	10.56 (0.06)
	1	2	0	14.72 (0.09)
	DPT	0	1	1
0		1	2	10.98 (0.02)
0		1	3	14.43 (0.02)
1		0	-1	-2.82 (0.10)
1		0	-2	-13.58 (0.10)
2		0	-1	2.07 (0.10)
1		1	0	11.43 (0.03)
1		2	0	15.87 (0.04)

^aThe p , q , and r are the stoichiometric coefficients corresponding to organotin(IV), 3,3-bis(1-methylimidazol-2-yl)propionate, and H^+ , respectively;


^bStandard deviations are given in parentheses.

the magnitudes of various residuals, as described elsewhere [27]. Table 1 lists the equilibrium constants together with their standard deviations as obtained from the program MINQUAD-75. The concentration distribution diagrams were obtained using the program SPECIES [28].

3. Results and Discussion

The protonation constants of 3,3-bis(1-methylimidazol-2-yl) propionic acid were determined by direct potentiometric measurements because all protonation reactions were observed to take place within the potentiometrically measurable pH range. Protonated 3,3-bis(1-methylimidazol-2-yl)propionate behaves as a triprotic acid (H_3A^{2+}), where the differential log protonation constants in aqueous solution were found to be 2.18, 4.20, and 7.11. The first constant is corresponding to the carboxylic group and the second and third constants are corresponding to the protonated imidazole groups.

The hydrolysis of the dimethyltin(IV) cation in aqueous solution was studied by several research groups [29–33]. The potentiometric data were fitted considering the formation of the species with stoichiometric coefficients (1 0 -1), (1 0 -2), (1 0 -3), (1 0 -4), and (2 0 -2) (Table 1). The hydrolysed species may form distannoxanes with a typical 4-membered ring (SnO)₂ as reported previously [34–36]. This species was not detected, which may be due the poor solubility. The dimerizing ability of the aqua-hydroxo complexes is described by the general equilibrium:



The dimerization constants can be determined [19] by

$$\log K_D = (\log \beta_{2\ 0\ -2}) - 2(\log \beta_{1\ 0\ -1}) = (-3.92) - 2(-3.39) = 2.86. \quad (4)$$

The potentiometric titration curves of 3,3-bis(1-methylimidazol-2-yl)propionate in the presence and absence of diorganotin(IV) are compared. The complex titration curve is significantly lower than 3,3-bis(1-methylimidazol-2-yl)propionate curve. This corresponds to the formation of a complex species through release of a hydrogen ion.

The complex formation equilibria of dimethyltin(IV) with 3,3-bis(1-methylimidazol-2-yl)propionate is characterized by fitting the potentiometric data to various models. The best model was found to be consistent with the formation of the complexes with stoichiometric coefficients (1 1 0), (1 2 0), and (1 1 -1).

The pK_a of a coordinated water molecule is calculated [18] by

$$pK_{a1} = \log \beta_{1\ 1\ 0} - \log \beta_{1\ 1\ -1}. \quad (5)$$

The calculated value is 4.77 and higher than that of water molecule coordinated to the free dimethyltin (IV) ion (3.39). This may be due to the elongation of the Sn(IV)-H₂O bond caused by the coordination of 3,3-bis(1-methylimidazol-2-yl)propionate. This may be explained on the basis that coordination of the ligand will decrease the electrophilicity of tin, and hence the coordinated water molecule will be weakly bound and consequently will be less acidic.

The concentration distribution diagram (Figure 1) shows that the species (1 1 0) is formed at low pH and predominates at pH 3.3 with an extent of formation of 46%. After pH 4.0, the monohydroxy species (1 1 -1) and hydrolysed species (1 0 -2) start to form and reach the formation percentage of 50% at pH 6.5 for (1 1 -1) species and 49% at pH 7.5 for (1 0 -2) species. The hydrolysed species (1 0 -3) is predominating after pH 10.

The hydrolysis of dibutyltin(IV) and diphenyltin(IV) ions is investigated in 50% dioxane-water solution. The potentiometric data are fitted considering the formation of the species (1 0 -1), (1 0 -2), and (2 0 -1). The monohydroxo-bridged





FIGURE 1: Concentration distribution of various species as a function of pH in the dimethyltin(IV) complexes, (at concentrations of 1.25 mmole/liter for DMT and 2.5 mmole/liter for BIMP) at 25°C.

dimer (2 0 -1) is assumed to form through dimerization of the tin(IV) via a hydroxo group, as given in



where R = a butyl- or phenyl-group.

The equilibrium constant for the dimerization reaction (6) is calculated by (7) and amounts to 2.98 for dibutyltin(IV) and 4.89 for diphenyltin(IV):

$$\log K_{\text{dimer}} = \log \beta_{2\ 0\ -1} - \log \beta_{1\ 0\ -1}. \quad (7)$$

The formation of the dihydroxo-bridged dimer (2 0 -2), found for dimethyltin(IV), is not favoured in the case of diphenyltin(IV) and dibutyltin(IV) ions. This may be accounted for on the basis of a steric interaction effect caused by the bulky butyl groups in the case of dibutyltin(IV) and phenyl groups in the case of diphenyltin(IV). This will cause the dimeric form (2 0 -2) to be strained and consequently energetically not favoured.

The pK_a of coordinated water molecules in dibutyltin(IV) and diphenyltin(IV) species determined in 50% dioxane-water solution are compared. The pK_a value ($-\log \beta_{1\ 0\ -1}$) for diphenyltin(IV) is lower than that of dibutyltin(IV). This may be explained on the premise that the butyl group is having a higher electron donating property. This will increase the electron density on the Sn atom, and consequently the coordinated water will be weakly bound to Sn. This will make the coordinated water less acidic. However, in diphenyltin(IV), the phenyl group is having a higher electron accepting property, which will increase the acidity of the coordinated water molecule.

The potentiometric data for diphenyltin(IV) and dibutyltin(IV) complexes with 3,3-bis(1-methylimidazol-2-yl)propionate are fitted with a model composed of the species (1 1 0) and (1 2 0). The hydrolysed form of the 1:1 complex (1 1 -1) is not formed. This may be due to the insolubility of the latter




FIGURE 2: Concentration distribution of various species as a function of pH in the dibutyltin(IV) complexes (at concentrations of 1.25 mmole/liter for DBT and 2.5 mmole/liter for BIMP) at 25°C.




FIGURE 3: Concentration distribution of various species as a function of pH in the DPT-BIMP system (at concentrations of 1.25 mmole/liter for DPT and 2.5 mmole/liter for BIMP) at 25°C.



species as a result of its electrical neutrality, and also, due to the hydrophobicity of the phenyl and butyl groups.

The concentration distribution diagram for dibutyltin(IV) complex, Figure 2, shows that the species (1 1 0) and (2 0 -1) are formed at low pH and reach a formation degree of 50% in the pH range 3-8 for (1 1 0) species and 15% at pH 4.2 for (2 0 -1) species. In the physiological pH range, the predominating species are (1 1 0) and (1 0 -1). The hydrolysed species (1 0 -2) and (1 2 0) species are formed after pH 10. From the biological point of view, it is interesting to note that the (1 1 0) species is predominating in the physiological pH range and consequently the interaction with DNA is feasible.


The concentration distribution diagram for diphenyltin(IV) complexes, Figure 3, reveals that tin(IV) is hydrolysed giving (2 0 -1) species with a maximum formation degree of 78% at pH 2.0. The complex species (1 1 0) reaches the maximum concentration of 52% in the pH range 2.8-8.0. Therefore, in the physiological pH range, the diphenyltin(IV) complex can interact with DNA constituents.

3.1. Displacement Reaction of 3,3-Bis(1-methylimidazol-2-yl)propionate Coordinated to Dimethyltin(IV) by Inosine and IMP. It was reported that DNA constituents [37, 38] have high affinity for dimethyltin(IV), dibutyltin(IV), and diphenyltin(IV), which may have important biological implications since the interaction with DNA is thought to be responsible

for the antitumour activity of related complexes [39]. The antitumour activity of a diorganotin-(amine) complex is based on the displacement of the amine by DNA [40]. Consequently, the equilibrium constant for such conversion is of biological significance. Consider inosine as a typical DNA constituent (presented by HB) and 3,3-bis(1-methylimidazol-2-yl)propionate (presented by H_3A^{2+}). The equilibria involved in complex-formation and displacement reactions may be presented as



$$\beta_{110}(CH_3)_2Sn(B)^+ = \frac{[(CH_3)_2Sn(B)^+]}{[(CH_3)_2Sn^{2+}][B^-]} \quad (11)$$



$$\beta_{110}(CH_3)_2Sn(A)^+ = \frac{[(CH_3)_2Sn(A)^+]}{[(CH_3)_2Sn^{2+}][A^-]} \quad (13)$$



The equilibrium constant for the displacement reaction is given by

$$K_{eq} = \frac{[(CH_3)_2Sn(B)^+][A^-]}{[(CH_3)_2Sn(A)^+][B^-]} \quad (15)$$

Substitution results in

$$K_{eq} = \frac{\beta_{110}^{(CH_3)_2Sn(B)^+}}{\beta_{110}^{(CH_3)_2Sn(A)^+}} \quad (16)$$

The $\log \beta_{110}$ value for dimethyltin(IV) complex with 3,3-bis(1-methylimidazol-2-yl)propionate $[(CH_3)_2Sn(A)^+]$, given in Table 1, amounts to 9.47. The corresponding $\log \beta_{110}$ for the inosine complex with the dimethyltin(IV) ions, taken from literature [22], is 8.66. Substitution in (16) results in $\log K_{eq} = -0.81$. In the same way, the equilibrium constant for the displacement reaction of coordinated 3,3-bis(1-methylimidazol-2-yl)propionate by inosine-5'-monophosphate was calculated using the formation constant of dimethyltin(IV) complex with inosine-5'-monophosphate, taken from the literature [22], amounting to 11.90. The corresponding $\log K_{eq}$ value is 2.43. The displacement constant values indicate the ability of inosine and inosine-5'-monophosphate to displace 3,3-bis(1-methylimidazol-2-yl)propionate from its diorganotin (IV) complexes and to what extent the amine complex can interact with the DNA constituent, the main target in tumour chemotherapy. Comparison of the displacement constant values for inosine and inosine-5'-monophosphate

showed that the nucleotide IMP has the higher value. This can be explained on the basis of the different columbic force of attraction between the dipositively charged diorganotin(IV) ion and IMP having extra negative charges on the phosphate group. The increase of columbic force of attraction between diorganotin(IV) and IMP will facilitate the release of coordinated 3,3-bis(1-methylimidazol-2-yl)propionate.

4. Conclusion

The present investigation describes complex formation equilibria of 3,3-bis(1-methylimidazol-2-yl)propionate with dimethyltin(IV), dibutyltin(IV), and diphenyltin(IV) ions. The results show the formation of 1:1 and 1:2 complexes. The displacement reaction of 3,3-bis(1-methylimidazol-2-yl)propionate coordinated to dimethyltin(IV) by DNA constituent as inosine and inosine-5'-monophosphate was investigated and a measure of the displacement was calculated. The results reveal to what extent DNA, the major target in tumour therapy, can displace the coordinated amine, 3,3-bis(1-methylimidazol-2-yl)propionate, and interact with dimethyltin(IV). These data are expected to contribute to the chemistry of organotin(IV) compounds as potential antitumor agents.

Acknowledgment

The authors are indebted to Professor Colin D. Hubbard for his assistance in the paper's preparation.

References

- [1] A. Kotsakis, D. Hatzidaki, L. Vamvakas et al., "A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer," *Anticancer Research*, vol. 30, no. 10, pp. 4335-4342, 2010.
- [2] W. A. Collier, "Zur experimentellen Therapie der Tumoren," *Zeitschrift für Hygiene und Infektionskrankheiten*, vol. 110, no. 1, pp. 169-174, 1929.
- [3] M. Gielen, "Organotin compounds and their therapeutic potential: a report from the organometallic chemistry department of the Free University of Brussels," *Applied Organometallic Chemistry*, vol. 16, no. 9, pp. 481-494, 2002.
- [4] A. Yahyia, A. Et-Touhami, R. Yahyaouia, and R. Touzani, "Synthesis, characterization by means of IR, 1H , ^{13}C -NMR and biological investigations on new diorganotin carboxylic acid derivatives," *Letters in Drug Design and Discovery*, vol. 7, no. 7, pp. 534-540, 2010.
- [5] X. Shang, J. Wu, A. J. L. Pombeiro, and Q. Li, "Mononuclear diorganotin(IV) complexes with arylhydroxamates: syntheses, structures and assessment of in vitro cytotoxicity," *Applied Organometallic Chemistry*, vol. 21, no. 11, pp. 919-925, 2007.
- [6] A. J. Crowe, P. J. Smith, and G. Atassi, "Investigations into the antitumour activity of organotin compounds. 2. Diorganotin dihalide and dipseudohalide complexes," *Inorganica Chimica Acta*, vol. 93, no. 4, pp. 179-184, 1984.
- [7] M. Gielen, C. Vanbellinthen, J. Gelan, and R. Willem, "Synthesis, characterization and antitumor activity of a series of diorganotin(IV) compounds of the type $Bu_2Sn(O-X-Y-O)$,"

- Bulletin des Sociétés Chimiques Belges*, vol. 97, no. 11-12, pp. 873–881, 1988.
- [8] S. Tabassum and C. Pettinari, "Chemical and biotechnological developments in organotin cancer chemotherapy," *Journal of Organometallic Chemistry*, vol. 691, no. 8, pp. 1761–1766, 2006.
- [9] N. Muhammad, Z. Rehman, S. Ali, A. Meetsma, and F. Shaheen, "Organotin(IV) 4-methoxyphenylethanoates: synthesis, spectroscopic characterization, x-ray structures and *in vitro* anticancer activity against human prostate cell lines (PC-3)," *Inorganica Chimica Acta*, vol. 362, no. 8, pp. 2842–2848, 2009.
- [10] M. Gielen and R. Willem, "Cytotoxic activity against a series of human tumour cell lines of some diorganotin(IV) 1,2-ethylenediamine N,N'-diacetates, N-(2-hydroxyethyl)- and N-(carbamoylmethyl)-iminodiacetates, and ortho-aminobenzoates," *Anticancer Research*, vol. 12, no. 1, pp. 269–271, 1992.
- [11] A. J. Crowe, "Antitumour activity of tin compounds," in *Metal Compounds in Cancer Therapy*, S. P. Fricker, Ed., pp. 147–179, Chapman and Hall, London, UK, 1994.
- [12] M. Gielen, "Tin-based antitumor drugs," *Metal-Based Drugs*, vol. 1, no. 2-3, pp. 213–219, 1994.
- [13] S. K. Hadjikakou and N. Hadjiliadis, "Antiproliferative and antitumor activity of organotin compounds," *Coordination Chemistry Reviews*, vol. 253, no. 1-2, pp. 235–249, 2009.
- [14] P. K. Sharma, K. Singh, S. Kumar et al., "Synthesis and anti-inflammatory evaluation of some pyrazolo[3,4-b]pyridines," *Medicinal Chemistry Research*, vol. 20, no. 2, pp. 239–244, 2011.
- [15] Z.-U. Zia-ur-Rehman, A. Shah, N. Muhammad, S. Ali, R. Qureshi, and I. S. Butler, "Synthesis, characterization and DNA binding studies of penta- and hexa-coordinated diorganotin(IV) 4-(4-nitrophenyl)piperazine-1-carbodithioates," *Journal of Organometallic Chemistry*, vol. 694, no. 13, pp. 1998–2004, 2009.
- [16] Z.-U. Rehman, A. Shah, N. Muhammad et al., "Synthesis, spectroscopic characterization, X-ray structure and evaluation of binding parameters of new triorganotin(IV) dithiocarboxylates with DNA," *European Journal of Medicinal Chemistry*, vol. 44, no. 10, pp. 3986–3993, 2009.
- [17] N. Muhammad, A. Shah, Z.-U. Zia-ur-Rehman et al., "Organotin(IV) 4-nitrophenylethanoates: synthesis, structural characteristics and intercalative mode of interaction with DNA," *Journal of Organometallic Chemistry*, vol. 694, no. 21, pp. 3431–3437, 2009.
- [18] A. S. Al Alousi, M. R. Shehata, M. M. Shoukry, and N. M. Mohamed, "Interaction of dimethyltin(IV) and trimethyltin(IV) with dehydroacetic acid," *Chemical Speciation and Bioavailability*, vol. 21, no. 1, pp. 1–6, 2009.
- [19] A. A. Al-Najjar, M. M. A. Mohamed, M. R. Shehata, and M. M. Shoukry, "Tripropyltin(IV) complexes with some selected bioligands in 50% V/V dioxane/water mixture," *Annali di Chimica*, vol. 96, no. 1-2, pp. 97–107, 2006.
- [20] A. A. Al-Najjar, M. M. A. Mohamed, and M. M. Shoukry, "Interaction of dipropyltin(IV) with amino acids, peptides, dicarboxylic acids and DNA constituents," *Journal of Coordination Chemistry*, vol. 59, no. 2, pp. 193–206, 2006.
- [21] M. M. A. Mohamed and M. M. Shoukry, "Interaction of diphenyltin(IV) dichloride with some selected bioligands," *Chemical and Pharmaceutical Bulletin*, vol. 49, no. 3, pp. 253–257, 2001.
- [22] O. Al-Flajji, M. R. Shehata, M. M. A. Mohamed, and M. M. Shoukry, "Interaction of dimethyltin(IV) with DNA constituents," *Monatshfte fur Chemie*, vol. 132, no. 3, pp. 349–366, 2001.
- [23] L. Peters, E. Hübner, and N. Burzlaff, "The new facial tripod ligand 3,3-bis(1-methylimidazol-2-yl)propionic acid and carbonyl complexes thereof containing manganese and rhenium," *Journal of Organometallic Chemistry*, vol. 690, no. 8, pp. 2009–2016, 2005.
- [24] R. G. Bates, *Determination of PH-Theory and Practice*, Wiley-Interscience, New York, NY, USA, 2nd edition, 1975.
- [25] M. M. Shoukry, W. M. Hosny, and M. M. Khalil, "Equilibrium and hydrolysis of α -amino acid esters in mixed-ligand complexes with N-(acetamido)-iminodiacetatecopper(II)," *Transition Metal Chemistry*, vol. 20, no. 3, pp. 252–255, 1995.
- [26] R. J. Motekaitis, A. E. Martell, and D. A. Nelson, "Formation and stabilities of cobalt(II) chelates of N-benzyl triamine Schiff bases and their dioxygen complexes," *Inorganic Chemistry*, vol. 23, no. 3, pp. 275–283, 1984.
- [27] P. Gans, A. Sabatini, and A. Vacca, "An improved computer program for the computation of formation constants from potentiometric data," *Inorganica Chimica Acta*, vol. 18, no. 1, pp. 237–239, 1976.
- [28] L. Pettit, Personal Communication.
- [29] G. Arena, R. Cali, A. Contino, A. Musumeci, S. Musumeci, and R. Purrello, "Coordination properties of dialkyltin (IV) in aqueous solution. Thermodynamic study of dimethyltin (IV) complexes with l-amino acids," *Inorganica Chimica Acta*, vol. 237, no. 1-2, pp. 187–191, 1995.
- [30] T. Natsume, S.-I. Aizawa, K. Hatano, and S. Funahashi, "Hydrolysis, polymerisation, and structure of dimethyltin(IV) in aqueous solution. Molecular structure of the polymer $[(\text{SnMe}_2)_2(\text{OH})_3]\text{ClO}_4$," *Journal of the Chemical Society, Dalton Transactions*, no. 19, pp. 2749–2753, 1994.
- [31] M. J. Hynes and M. O'Dowd, "Interactions of the trimethyltin(IV) cation with carboxylic acids, amino acids, and related ligands," *Journal of the Chemical Society, Dalton Transactions*, no. 3, pp. 563–566, 1987.
- [32] C. de Stefano, C. Foti, A. Gianguzza, M. Martino, L. Pellerito, and S. Sammartano, "Hydrolysis of $(\text{CH}_3)_2\text{Sn}^{2+}$ in different ionic media: salt effects and complex formation," *Journal of Chemical and Engineering Data*, vol. 41, no. 3, pp. 511–515, 1996.
- [33] C. Foti, A. Gianguzza, F. J. Millero, and S. Sammartano, "The speciation of $(\text{CH}_3)_2\text{Sn}^{2+}$ in electrolyte solution containing the major components of natural waters," *Aquatic Geochemistry*, vol. 5, no. 4, pp. 381–398, 1999.
- [34] N. Kourkoumelis, A. Hatzidimitriou, and D. Kovala-Demertzi, "The crystal structure of di-2-aminopyrimidinium tetraphenyldichloro(μ -oxo)distannate," *Journal of Organometallic Chemistry*, vol. 514, no. 1-2, pp. 163–167, 1996.
- [35] C. K. Chu and J. D. Murray, "Hydrolysis products of dibutyltin dichlorides," *Journal of the Chemical Society A*, pp. 360–367, 1971.
- [36] L. Pellerito and L. Nagy, "Organotin(IV)²⁺ complexes formed with biologically active ligands: equilibrium and structural studies, and some biological aspects," *Coordination Chemistry Reviews*, vol. 224, no. 1-2, pp. 111–150, 2002.
- [37] L. Ghys, M. Biesemans, M. Gielen et al., "Multinuclear 1D and 2D NMR investigations on the interaction between the pyrimidic nucleotides 5'-CMP, 5'-dCMP, and 5'-UMP and diethyltin dichloride in aqueous medium," *European Journal of Inorganic Chemistry*, no. 3, pp. 513–522, 2000.
- [38] F. Arjmand, G. C. Sharma, F. Sayeed, M. Muddassir, and S. Tabassum, "De novo design of chiral organotin cancer drug candidates: validation of enantiopreferential binding to molecular target DNA and 5'-GMP by UV-visible, fluorescence, ¹H

and ^{31}P NMR," *Journal of Photochemistry and Photobiology B*, vol. 105, no. 3, pp. 167–174, 2011.

- [39] A. A. El-Tombary, Y. S. Abdel-Ghany, A. S. F. Belal, S. A. Shams El-Dine, and F. S. G. Soliman, "Synthesis of some substituted furan-2(5H)-ones and derived quinoxalinones as potential anti-microbial and anti-cancer agents," *Medicinal Chemistry Research*, vol. 20, no. 7, pp. 865–876, 2011.
- [40] M. Nath, H. Singh, G. Eng, and X. Song, "Interaction of organotin(IV) moieties with nucleic acid constituent: synthesis, structural characterization and anti-inflammatory activity of tri-*i*-propyltin(IV) and diorganotin(IV) derivatives of guanosine," *Inorganic Chemistry Communications*, vol. 14, no. 9, pp. 1381–1385, 2011.